RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intercept Pharmaceuticals Stock

Intercept Pharmaceuticals P/S 2024

Intercept Pharmaceuticals P/S

1.74

Ticker

ICPT

ISIN

US45845P1084

WKN

A1J5U0

As of Oct 9, 2024, Intercept Pharmaceuticals's P/S ratio stood at 1.74, a 62.62% change from the 1.07 P/S ratio recorded in the previous year.

The Intercept Pharmaceuticals P/S history

Intercept Pharmaceuticals Aktienanalyse

What does Intercept Pharmaceuticals do?

Intercept Pharmaceuticals Inc is a biotechnology company based in New York City that focuses on the discovery and development of therapeutics for the treatment of chronic liver diseases. The company was founded in 2002 and has since brought a variety of innovative drugs to the market. The business model of Intercept Pharmaceuticals Inc is based on the invention, development, and marketing of drugs that specifically target certain disease conditions. They primarily focus on the development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These two diseases are prevalent worldwide and pose significant health problems in many Western societies. Intercept Pharmaceuticals Inc has already achieved significant success in the treatment of NAFLD and NASH. The various divisions of Intercept Pharmaceuticals Inc can be divided into research, development of new products, sale of existing drugs, and collaboration with partners and other companies. In research, the company strives to develop the most effective and safe medications, utilizing state-of-the-art technologies and research methods. The main products of Intercept Pharmaceuticals Inc are Ocaliva and obeticholic acid. Ocaliva is a medication used to treat primary biliary cholangitis, a disease that causes inadequate movement of bile through the liver and its accumulation in the body. Ocaliva helps improve bile production and alleviate the symptoms of this disease. Obeticholic acid is a new approach to the treatment of NASH and is currently being tested in clinical trials. Intercept Pharmaceuticals Inc works closely with other companies and organizations to ensure the most effective therapy for patients worldwide. Interaction with industry colleagues, scientific institutions, and experts in the field of medical research allows for faster development of new products that benefit patients. Overall, Intercept Pharmaceuticals Inc has achieved an impressive track record in recent years. The company has established a strong position in the field of liver diseases by advancing research and development in innovative ways. The focus on NAFLD and NASH allows Intercept Pharmaceuticals Inc to play a leading role in this market segment and provide patients with effective medications for their conditions. In summary, Intercept Pharmaceuticals Inc is a company dedicated to the development and marketing of products for the treatment of liver diseases. Through the use of innovative technologies and close collaboration with other companies and organizations, Intercept Pharmaceuticals Inc has already achieved significant success in the development of new medications. The company has established a strong position in this market segment and aims to develop further innovative products to combat liver diseases in the future. Intercept Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Intercept Pharmaceuticals's P/S Ratio

Intercept Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Intercept Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Intercept Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Intercept Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Intercept Pharmaceuticals stock

What is the price-to-earnings ratio of Intercept Pharmaceuticals?

The price-earnings ratio of Intercept Pharmaceuticals is currently 1.74.

How has the price-earnings ratio of Intercept Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Intercept Pharmaceuticals has increased by 62.62% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Intercept Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Intercept Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Intercept Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Intercept Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Intercept Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Intercept Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Intercept Pharmaceuticals?

Some factors that influence the price-earnings ratio of Intercept Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Intercept Pharmaceuticals pay?

Over the past 12 months, Intercept Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intercept Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Intercept Pharmaceuticals?

The current dividend yield of Intercept Pharmaceuticals is .

When does Intercept Pharmaceuticals pay dividends?

Intercept Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intercept Pharmaceuticals?

Intercept Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Intercept Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intercept Pharmaceuticals located?

Intercept Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intercept Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intercept Pharmaceuticals from 10/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/9/2024.

When did Intercept Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/9/2024.

What was the dividend of Intercept Pharmaceuticals in the year 2023?

In the year 2023, Intercept Pharmaceuticals distributed 0 USD as dividends.

In which currency does Intercept Pharmaceuticals pay out the dividend?

The dividends of Intercept Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Intercept Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Intercept Pharmaceuticals

Our stock analysis for Intercept Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intercept Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.